#### Pamela Maffioli

#### List of Publications by Citations

Source: https://exaly.com/author-pdf/4447585/pamela-maffioli-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

182 4,509 37 57 h-index g-index citations papers 5.98 195 5,340 4.7 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
182	Sulfonylureas and their use in clinical practice. <i>Archives of Medical Science</i> , <b>2015</b> , 11, 840-8	2.9	220
181	EGlucosidase inhibitors and their use in clinical practice. Archives of Medical Science, 2012, 8, 899-906	2.9	194
180	Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases. <i>Molecular Diagnosis and Therapy</i> , <b>2016</b> , 20, 335-45	4.5	141
179	Anti-obesity drugs: a review about their effects and their safety. <i>Expert Opinion on Drug Safety</i> , <b>2012</b> , 11, 459-71	4.1	129
178	Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. <i>Expert Opinion on Biological Therapy</i> , <b>2012</b> , 12, 1113-24	5.4	123
177	Matrix metalloproteinase-2 and -9 levels in obese patients. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2008</b> , 15, 219-24		107
176	Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , <b>2016</b> , 111, 394-404	10.2	102
175	Exenatide versus glibenclamide in patients with diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2010</b> , 12, 233-40	8.1	97
174	The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 153-161	7	96
173	Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , <b>2010</b> , 59, 887-95	12.7	93
172	A role for quercetin in coronavirus disease 2019 (COVID-19). <i>Phytotherapy Research</i> , <b>2021</b> , 35, 1230-123	3 <b>6</b> 6.7	78
171	Adipocytokine levels in obese and non-obese subjects: an observational study. <i>Inflammation</i> , <b>2013</b> , 36, 914-20	5.1	71
170	Effects of berberine on lipid profile in subjects with low cardiovascular risk. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 475-82	5.4	64
169	Exosomes: Nanoparticulate tools for RNA interference and drug delivery. <i>Journal of Cellular Physiology</i> , <b>2017</b> , 232, 1660-1668	7	62
168	Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. <i>European Journal of Pharmacology</i> , <b>2011</b> , 666, 251-6	5.3	57
167	Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Pharmacological Research</i> , <b>2015</b> , 102, 63-70	10.2	54
166	Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, Etell function and insulin resistance in type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , <b>2012</b> , 98, 51-60	7.4	54

# (2016-2012)

165	Peroxisome proliferator-activated receptor-[PPAR-Dagonists on glycemic control, lipid profile and cardiovascular risk. <i>Current Molecular Pharmacology</i> , <b>2012</b> , 5, 272-81	3.7	51	
164	Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. <i>Nutrition Research</i> , <b>2013</b> , 33, 622-8	4	49	
163	Exenatide plus metformin compared with metformin alone on Etell function in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , <b>2012</b> , 29, 1515-23	3.5	48	
162	Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 1221-36	3.5	47	
161	Ellagic Acid and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 928, 473-479	3.6	47	
160	Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. <i>Hormone and Metabolic Research</i> , <b>2010</b> , 42, 663-9	3.1	45	
159	Dipeptidyl peptidase-4 inhibitors: 3 years of experience. <i>Diabetes Technology and Therapeutics</i> , <b>2012</b> , 14, 350-64	8.1	45	
158	Naturally occurring anti-cancer agents targeting EZH2. Cancer Letters, 2017, 400, 325-335	9.9	44	
157	Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 2807-2816	2.3	44	
156	Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. <i>Journal of Clinical Lipidology</i> , <b>2012</b> , 6, 553-64	4.9	43	
155	Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. <i>Endocrine Journal</i> , <b>2010</b> , 57, 777-86	2.9	42	
154	Dietary and nutraceutical approach to type 2 diabetes. <i>Archives of Medical Science</i> , <b>2014</b> , 10, 336-44	2.9	41	
153	Vildagliptin added to metformin on Etell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. <i>Diabetes Technology and Therapeutics</i> , <b>2012</b> , 14, 475-8	48.1	41	
152	Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. <i>European Journal of Pharmacology</i> , <b>2011</b> , 651, 240-50	5.3	41	
151	Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , <b>2016</b> , 212, 160-8	3.2	39	
150	GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. <i>Current Clinical Pharmacology</i> , <b>2012</b> , 7, 214-28	2.5	39	
149	A Clinical Trial about a Food Supplement Containing Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	39	
148	Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. <i>Drugs</i> , <b>2016</b> , 76, 947-56	12.1	38	

147	Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. <i>Current Topics in Medicinal Chemistry</i> , <b>2014</b> , 14, 200-6	3	38
146	Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 2359-2366	2.3	38
145	Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 344-53	13.6	37
144	Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 1495-506	5.4	37
143	Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. <i>Heart and Vessels</i> , <b>2009</b> , 24, 204-10	2.1	37
142	Piperine and Its Role in Chronic Diseases. Advances in Experimental Medicine and Biology, 2016, 928, 173	3-3.864	37
141	Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. <i>Hormone and Metabolic Research</i> , <b>2010</b> , 42, 8-13	3.1	36
140	Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2009</b> , 11, 1091-9	6.7	36
139	Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2012</b> , 37, 187-95	2.2	35
138	Curcumin: A Natural Pan-HDAC Inhibitor in Cancer. Current Pharmaceutical Design, 2018, 24, 123-129	3.3	34
137	Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 1973-83	2.5	33
136	Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 16	4 <sup>2</sup> 7 <sup>2</sup> 1	33
135	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. <i>Clinical and Investigative Medicine</i> , <b>2009</b> , 32, E124-32	0.9	32
134	Effects of n-3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. <i>BioFactors</i> , <b>2016</b> , 42, 316-22	6.1	32
133	Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. <i>Hypertension Research</i> , <b>2011</b> , 34, 145-51	4.7	31
132	Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 607-15	2.5	30
131	Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2010</b> , 35, 565-79	2.2	29
130	Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. <i>Internal Medicine</i> , <b>2010</b> , 49, 1717-25	1.1	29

# (2020-2011)

129	Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. <i>Metabolism: Clinical and Experimental</i> , <b>2011</b> , 60, 421-9	12.7	28	
128	Effects of thiazolidinediones and sulfonylureas in patients with diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2010</b> , 12, 491-501	8.1	28	
127	Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. <i>Hormone and Metabolic Research</i> , <b>2011</b> , 43, 505-12	3.1	27	
126	Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 807-18	3.8	27	
125	A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 2127-35	1.9	26	
124	Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 1971-82	4	25	
123	Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. <i>Atherosclerosis</i> , <b>2015</b> , 239, 87-92	3.1	24	
122	Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. <i>Microvascular Research</i> , <b>2010</b> , 80, 110-5	3.7	24	
121	Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 1481-1488	4.4	23	
120	Prevalence and associations of erectile dysfunction in a sample of Italian males with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2015</b> , 108, 329-35	7.4	23	
119	Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , <b>2014</b> , 63, 957-67	12.7	23	
118	Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. <i>Fundamental and Clinical Pharmacology</i> , <b>2014</b> , 28, 221-9	3.1	23	
117	Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. <i>Clinical Cardiology</i> , <b>2012</b> , 35, 359-64	3.3	23	
116	Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. <i>Internal Medicine</i> , <b>2013</b> , 52, 2179-87	1.1	23	
115	Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. <i>Fundamental and Clinical Pharmacology</i> , <b>2011</b> , 25, 642-51	3.1	22	
114	Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. <i>Microvascular Research</i> , <b>2010</b> , 79, 144-9	3.7	22	
113	Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 1239-47	4	22	
112	Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markErs in the progreSsion of dlabeteS in obese paTleNts (The RESISTIN trial). <i>Cytokine</i> , <b>2020</b> , 127, 154947	4	22	

111	Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. <i>Hypertension Research</i> , <b>2011</b> , 34, 1321-6	4.7	21
110	Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2011</b> , 4, 263-71	3.4	21
109	Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. <i>Hypertension Research</i> , <b>2010</b> , 33, 790-5	4.7	21
108	Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2581-91	4	21
107	Improvement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 819-34	3.8	20
106	The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. <i>Clinical Nutrition</i> , <b>2016</b> , 35, 1091-5	5.9	19
105	Variation in inflammatory markers and glycemic parameters after 12[months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 817-26	5.8	19
104	Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2011</b> , 91, 265-70	7.4	19
103	Berberis aristata/Silybum marianum fixed combination (Berberol([] )) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. <i>Phytomedicine</i> , <b>2015</b> , 22, 231-7	6.5	18
102	A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and Etell function. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2433-42	4	18
101	Candesartan effect on inflammation in hypertension. <i>Hypertension Research</i> , <b>2010</b> , 33, 209-13	4.7	18
100	Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. <i>Current Medical Research and Opinion</i> , <b>2012</b> , 28, 1435-45	2.5	18
99	Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60@ study. <i>Metabolism: Clinical and Experimental</i> , <b>2009</b> , 58, 1059-66	12.7	18
98	Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q on lipid levels: a randomized, double-blind, placebo controlled study. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 1585-1592	4.4	17
97	Drug safety evaluation of amlodipine. Expert Opinion on Drug Safety, 2011, 10, 795-804	4.1	17
96	A review about biomarkers for the investigation of vascular function and impairment in diabetes mellitus. <i>Vascular Health and Risk Management</i> , <b>2016</b> , 12, 415-419	4.4	17
95	Effects of n-3 PUFA on insulin resistance after an oral fat load. <i>European Journal of Lipid Science and Technology</i> , <b>2011</b> , 113, 950-960	3	16
94	Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. Diabetes Technology and Therapeutics, <b>2009</b> , 11, 159-69	8.1	16

# (2020-2017)

93	Curcuminoids Lower Plasma Leptin Concentrations: A Meta-analysis. <i>Phytotherapy Research</i> , <b>2017</b> , 31, 1836-1841	6.7	15
92	Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. <i>Archives of Medical Research</i> , <b>2008</b> , 39, 412-9	6.6	15
91	Auraptene and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 929, 399-407	3.6	14
90	A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. <i>Diabetes Technology and Therapeutics</i> , <b>2013</b> , 15, 214-22	8.1	14
89	Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2013</b> , 91, 724-32	2.4	14
88	Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. <i>Biomedicine and Pharmacotherapy</i> , <b>2009</b> , 63, 723-33	7.5	14
87	Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. <i>Metabolism: Clinical and Experimental</i> , <b>2008</b> , 57, 1552-7	12.7	14
86	Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. <i>Pharmacological Research</i> , <b>2015</b> , 100, 127-34	10.2	13
85	Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , <b>2016</b> , 16, 66	2.3	13
84	Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial. <i>Phytomedicine</i> , <b>2018</b> , 42, 75-82	6.5	12
83	Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. <i>Hypertension Research</i> , <b>2015</b> , 38, 690-4	4.7	12
82	Effects of canrenone in patients with metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 2161-9	4	12
81	Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	12
80	Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2013</b> , 25, 1113-22	2.2	12
79	Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. <i>Expert Review of Cardiovascular Therapy</i> , <b>2010</b> , 8, 835-43	2.5	12
78	Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2441-8	4	12
77	Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 1351-8	4	12
76	Change of some oxidative stress parameters after supplementation with whey protein isolate in patients with type 2 diabetes. <i>Nutrition</i> , <b>2020</b> , 73, 110700	4.8	12

75	Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1380-1396	3.8	11
74	Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 341-7	6.7	11
73	Quercetin Phytosome as a potential candidate for managing COVID-19. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67, 190-195	3	11
7 <del>2</del>	Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , <b>2010</b> , 13, 378-90	3.4	10
71	Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. <i>Internal Medicine</i> , <b>2009</b> , 48, 265-71	1.1	10
70	Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglicemic patients. <i>Phytotherapy Research</i> , <b>2019</b> , 33, 791-797	6.7	9
69	Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. <i>European Journal of Pharmacology</i> , <b>2015</b> , 766, 31-6	5.3	9
68	An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2020</b> , 13, 653-661	3.4	9
67	Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study. <i>Drug Design, Development and Therapy</i> , <b>2019</b> , 13, 3647-3655	4.4	9
66	Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction. <i>Endocrine Journal</i> , <b>2012</b> , 59, 611-9	2.9	9
65	Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 1091-9	4	9
64	High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 3425-3434	4.4	8
63	Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2011</b> , 36, 592-601	2.2	8
62	Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 629-36	4	8
61	Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2015</b> , 10, 297-304	4.1	7
60	Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. <i>European Journal of Pharmaceutical Sciences</i> , <b>2014</b> , 51, 26-33	5.1	7
59	Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. <i>Journal of the American Society of Hypertension</i> , <b>2013</b> , 7, 32-9		7
58	A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. <i>Cardiovascular Diabetology</i> , <b>2015</b> , 14, 95	8.7	7

#### (2015-2015)

57	The effects of canrenone on inflammatory markers in patients with metabolic syndrome. <i>Annals of Medicine</i> , <b>2015</b> , 47, 47-52	1.5	7	
56	Effect of Sibutramine on Plasma C-Reactive Protein, Leptin and Adipon ectin Concentrations: A Systematic Review and Meta-Analysis of Randomized Contr olled Trials. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 870-878	3.3	7	
55	Lipid-lowering nutraceuticals update on scientific evidence. <i>Journal of Cardiovascular Medicine</i> , <b>2020</b> , 21, 845-859	1.9	7	
54	Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes. <i>Therapeutics and Clinical Risk Management</i> , <b>2018</b> , 14, 1637-1640	2.9	7	
53	Effects of two different dialytic treatments on inflammatory markers in people with end-stage renal disease with and without type 2 diabetes mellitus. <i>Cytokine</i> , <b>2017</b> , 92, 75-79	4	6	
52	Olmesartan Combined With Amlodipine on Oxidative Stress Parameters in Type 2 Diabetics, Compared With Single Therapies: A Randomized, Controlled, Clinical Trial. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3084	1.8	6	
51	Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate. <i>Archives of Medical Science</i> , <b>2013</b> , 9, 238-42	2.9	6	
50	Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy. <i>Journal of Clinical Pharmacology</i> , <b>2019</b> , 59, 1391-1399	2.9	5	
49	Ascophyllum Nodosum, Fucus Vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2019</b> , 12, 1861-1865	3.4	5	
48	Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. <i>Inflammation</i> , <b>2014</b> , 37, 154-62	5.1	5	
47	Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study. <i>Journal of the American Society of Hypertension</i> , <b>2014</b> , 8, 422-8		5	
46	Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. <i>Clinical and Experimental Hypertension</i> , <b>2013</b> , 35, 301-7	2.2	5	
45	Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial. <i>Cardiovascular Therapeutics</i> , <b>2017</b> , 35, 47-54	3.3	5	
44	Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial. <i>Pharmacotherapy</i> , <b>2015</b> , 35, 983-90	5.8	5	
43	Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI). <i>Endocrine Journal</i> , <b>2009</b> , 56, 571-8	2.9	5	
42	Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 605691	4.9	5	
41	Quercetin Phytosome as a potential candidate for managing COVID-19. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67,	3	5	
40	Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus. <i>Journal of Clinical Pharmacology</i> , <b>2015</b> , 55, 409-14	2.9	4	

39	Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention. <i>Drug Design, Development and Therapy</i> , <b>2020</b> , 14, 5367-	-5 <del>3</del> 174	4
38	Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients. <i>Drug Design</i> ,	4.4	4
37	Evaluation of the Effects of Mesoglycan on Some Markers of Endothelial Damage and Walking Distance in Diabetic Patients with Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	4
36	Assessment and management of left ventricular hypertrophy in Type 2 diabetes patients with high blood pressure. <i>Expert Review of Cardiovascular Therapy</i> , <b>2013</b> , 11, 719-28	2.5	4
35	Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. <i>Expert Opinion on Drug Safety</i> , <b>2013</b> , 12, 621-9	4.1	4
34	Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 371-84	4	4
33	A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients. <i>Drug Design, Development and Therapy,</i> <b>2018</b> , 12, 2611-2616	4.4	4
32	Evaluation of BAG3 levels in healthy subjects, hypertensive patients, and hypertensive diabetic patients. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 1791-1795	7	3
31	Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. <i>Scientific Reports</i> , <b>2015</b> , 5, 12603	4.9	3
30	Glyco-metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study). <i>Diabetes/Metabolism Research and Reviews</i> , <b>2020</b> , 36, e3219	7.5	3
29	EXAMINE: targeting risk and treatment in diabetes. <i>Lancet, The</i> , <b>2015</b> , 386, 1443	40	2
28	Nifedipine and telmisartan for the treatment of hypertension: the TALENT study. <i>Expert Review of Cardiovascular Therapy</i> , <b>2011</b> , 9, 1499-503	2.5	2
27	Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial. <i>International Journal for Vitamin and Nutrition Research</i> , <b>2020</b> , 1-10	1.7	2
26	Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 582556	8.4	2
25	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effectiveness of a Food Supplement Containing Creatine and D-Ribose Combined with a Physical Exercise Program in Increasing Stress Tolerance in Patients with Ischemic Heart Disease. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	2
24	Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study. <i>Pharmacological Research</i> , <b>2019</b> , 141, 46-52	10.2	2
23	Ilex paraguariensis, white mulberry and chromium picolinate in patients with pre-diabetes. <i>Phytotherapy Research</i> , <b>2020</b> , 34, 1377-1384	6.7	2
22	Retraction notice to "Evaluation of the positive effects on insulin-resistance and Etell measurements of vildagliptin in addition to metformin in type 2 diabetic patients" [Pharmacol. Res. 73 (2013) 20-26]. <i>Pharmacological Research</i> , <b>2017</b> , 121, 255	10.2	1

21	Inhaled insulin: weighing the pros and cons. Lancet Diabetes and Endocrinology, the, 2015, 3, 834-5	18.1	1
20	Glibenclamide and cardio-metabolic risk: a systematic review. <i>International Journal of Diabetes in Developing Countries</i> , <b>2014</b> , 34, 61-68	0.8	1
19	Response to an oral fat load and effects on lipid profile, glycemia and high-sensitivity C-reactive protein after soybean extract consumption. <i>Archives of Medical Science</i> , <b>2018</b> , 14, 760-765	2.9	1
18	Bicarbonate dialysis compared to hemodiafiltration on glycemic excursions in patients with end-stage renal disease with and without type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , <b>2015</b> , 29, 1136-41	3.2	1
17	A curious case of hypoglycaemia. Archives of Medical Science, 2013, 9, 752-4	2.9	1
16	Effects of a nutraceutical combination of monacolin, Ebryzanol and Elaminobutyric acid on lipid profile and C-reactive protein in mice. <i>Archives of Medical Science</i> , <b>2019</b> , 15, 792-796	2.9	1
15	Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles <b>2015</b> , 1-24		1
14	Metabolic Actions of a Supplement of Ilex Paraguariensis (An Extract of the Leaf Standardized to 2% I-Deoxinojirimcina), White Mulberry and Chromium Picolinate in Nondiabetic Subects with Dysglycemia: A Randomized Trial. <i>Life</i> , <b>2021</b> , 11,	3	1
13	Effects of experimental colitis in rats on incretin levels, inflammatory markers, and enteric neuronal function. <i>Archives of Medical Science</i> , <b>2021</b> , 17, 1087-1092	2.9	O
12	Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid, L. and , Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction <i>Frontiers in Endocrinology</i> , <b>2022</b> ,	5.7	O
11	Retraction notice to "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study". <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 1248	3.2	
10	Pharmacotherapy for Obesity <b>2014</b> , 261-277		
9	Diabetes: safety and efficacy of albiglutide-results from two trials. <i>Nature Reviews Endocrinology</i> , <b>2014</b> , 10, 514-6	15.2	
8	Retraction notice to "Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies": J Am Soc Hypertens 7 (2013) 32-39. <i>Journal of the American Society of</i>		
7	Retraction notice to "Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study": J Am Soc Hypertens 8 (2014) 422-428. <i>Journal of the American Society of Hypertension</i> , <b>2015</b> , 9, 822		
6	6D.07. Journal of Hypertension, <b>2015</b> , 33, e84	1.9	
5	Optimizing glycemic control: clinical utility of exenatide prolonged release injection. <i>Research and Reports in Endocrine Disorders</i> , <b>2012</b> , 41		
4	Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease. <i>European Medical Journal Diabetes</i> ,70-78	1	

- 3 Nutraceutical Herbs and Insulin Resistance **2019**, 223-242
- Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles **2016**, 3-26
- Retraction notice to "Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammatin" [European Journal of Pharmaceutical Sciences 51C (2013) 26-33].

  European Journal of Pharmaceutical Sciences, 2018, 123, 584